T2 Biosystems Announces Participation at 2010 BIO International Convention

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- T2 Biosystems, Inc., a company developing the first point-of-care medical diagnostic products that enable rapid molecular and immunodiagnostic testing on a single instrument, today announced, that it will be participating in a session on new diagnostics for the new healthcare system, taking place at the 2010 BIO International Convention in Chicago.

On Thurs., May 6 from 10-11:30am, John McDonough, CEO of T2 Biosystems, will be making a presentation during a Session entitled "New Diagnostics for a New Health Care System” in Room S402-A at the McCormick Place convention center.

New, breakthrough technologies are producing the next generation of novel, accessible and versatile diagnostics that have the potential to revolutionize how patients are diagnosed and, ultimately, treated. The key success factor for emerging diagnostics is enabling better patient and economic outcomes than the current diagnostic technologies on the market; and the demand is growing due to the recent healthcare reform.

Mr. McDonough will be among speakers who will provide an overview on the current diagnostic marketplace and the need for value disruption against the health care reform landscape. Panel members will review their respective technologies and discuss the opportunities for each technology to change the diagnostic and treatment paradigm.

The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offering key networking and partnering opportunities, and provides insights and inspiration on the major trends in the industry today. For more information on BIO 2010 visit http://convention.bio.org

About T2 Biosystems

T2 Biosystems is a private biotechnology company developing next-generation medical diagnostic products using its proprietary technology, combining nanotechnology and miniaturized magnetic resonance (MR) technology to provide rapid, accurate and portable diagnostics. T2 Biosystems was founded in 2006 by renowned researchers from the Massachusetts Institute of Technology, Harvard University, Harvard Medical School and Massachusetts General Hospital, and has assembled a world-class team, board of directors and scientific advisory board that collectively have a proven track record of translating technologic innovations into breakthrough products, building significant corporate value. T2 Biosystems is located in Cambridge, Massachusetts. For more information, please visit the company's website at www.t2biosystems.com



CONTACT:

The Yates Network
Adriana Jenkins, 617-744-1713

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Technology  Nanotechnology  Health  Biotechnology  Genetics  Infectious Diseases  Medical Devices  Pharmaceutical  Other Health

MEDIA:

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.